FindAPhD Weekly PhD Newsletter | JOIN NOW FindAPhD Weekly PhD Newsletter | JOIN NOW

Enable the global access to safe and efficacious antileishmanial nanomedicine through cost-effective manufacturing methods


   School of Pharmacy

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
  Dr Justin Tian  Applications accepted all year round  Self-Funded PhD Students Only

About the Project

Leishmaniasis is one of the NTDs, affecting over 1 billion people across 90 countries in the world. Caused by sand fly borne kinetoplastid protozoan parasites with infection leading to a wide spectrum of diseases, including cutaneous leishmaniasis (CL) to more fatal visceral leishmaniasis (VL).1 The global burden of VL has decreased in the past decade thanks to the collaborative elimination efforts driven by the United Nation, World Health Organisation, governments, charities and medicine manufacturers. However, in the same period, CL cases have increased dramatically (0.7 – 1.0 million per year) largely due to forced migration in conflict zones and lack of standard healthcare facility. Vaccines are absent and drug therapy is limited. The current treatment of CL is still relied on 70 years old medicines such as sodium stibogluconate and meglumine antimoniate, despite their severe side-effects, high cost (parenteral administration), and the increased drug resistance.2,3

Over the last few years, we have established a novel integrated approach for the development and screen of new drug candidates and their suitable nanoformulations. In this highly interdisciplinary project, you will be working with the team at Queen’s University Belfast and Prof Paul Denny at Durham University with the aim to discover and develop new therapy for the treatment of Leishmaniasis.

Studentship 1: design, characterisation and optimisation of the novel nanoformulations

Studentship 2: in vitro and ex-vivo evaluations on novel nanoformulations for antileishmanial activities.


References

(1) WHO. The Leishmaniases: timeline of facts and the formidable quest for disease control https://www.who.int/neglected_diseases/news/Leishmaniasis-timeline-of-facts-and-the-quest-disease-control/en/ (accessed Feb 14, 2019).
(2) Croft, S. L.; Coombs, G. H. Leishmaniasis - Current Chemotherapy and Recent Advances in the Search for Novel Drugs. Trends Parasitol. 2003, 19 (11), 502–508. https://doi.org/10.1016/j.pt.2003.09.008.
(3) Norcliffe, J. L.; Mina, J. G.; Alvarez, E.; Cantizani, J.; De Dios-Anton, F.; Colmenarejo, G.; Valle, S. G. Del; Marco, M.; Fiandor, J. M.; Martin, J. J.; Steel, P. G.; Denny, P. W. Identifying Inhibitors of the Leishmania Inositol Phosphorylceramide Synthase with Antiprotozoal Activity Using a Yeast-Based Assay and Ultra-High Throughput Screening Platform. Sci. Rep. 2018, 8 (1), 1–10. https://doi.org/10.1038/s41598-018-22063-9.
PhD saved successfully
View saved PhDs